London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have been posted to Shareholders of Chi-Med (“Shareholders”). The documents can be accessed from the website of Chi-Med (www.chi-med.com). Due […]
Contents Corporate Information Chairman’s Statement 2019 Operating Highlights 2019 Financial Highlights Financial Review Operations Review Innovation Platform Commercial Platform Use of Non-GAAP Financial Measures and Reconciliation Biographical Details Of Directors Report of the Directors Corporate Governance Report Form 20-F (Including Financial Statements) Information For Shareholders
Announcement released: 12 noon GMT (7am EST / 8pm HKT ) >> View Announcement << Presentation webcast & call: 1pm GMT (8am EST / 9pm HKT) Watch the Webcast Replay To participate by phone, please use one of the following numbers. Participant Access Code is “413486“. United Kingdom (Local) 020 3936 2999 China (Local): 010 5387 […]
Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical company with eight oncology drug candidates in development around the world and a deep commercial presence in China, today […]
London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesday, March 3, 2020. The time has been revised to 12:00 noon Greenwich Mean Time (GMT) / 7:00 am […]
The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time (GMT). A presentation for analysts and […]
London: Saturday, November 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shared analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESMO Asia”) on November 22 to 24, 2019 in Singapore. Savolitinib: the TATTON study was selected as a late-breaking presentation in the Presidential […]
Presentation Date: Monday Nov 25, 2019 Presentation Time: 11:30 am (HKT) Location: Conrad Hotel, Hong Kong
Title: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep) Presenting Author: Jianming Xu, Head of the Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of the PLA Abstract #: LBA76 Date & Time: Sunday, September 29, 2019, 16:30 CEST […]
Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potential submission of surufatinib New Drug Application (“NDA”) by year end 2019 for non-pancreatic NET tumors in China – – […]
Presentation Title : Association Between Hand-Foot Skin Reaction and Survival Benefit of Fruquintinib in FRESCO Trial Presenting Author: Yuxian Bai, Harbin Medical University Cancer Hospital Other Authors: Jin Li, Shukui Qin, Yanhong Deng, Lei Yang, Rui-hua Xu, Zhendong Chen, Haijun Zhong, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, […]
Presentation Title : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis Presenting Author: Shukui Qin, Nanjing Chinese Medicine University Affiliated Bayi Hospital Other Authors: Jin Li, Rui-Hua Xu, Lin Shen, Jianming Xu, Yuxian Bai, Yanhong Deng, Lei Yang, Zhen-dong Chen, Haijun Zhong, Hongming Pan, […]
London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (“CSCO”) on September 18 to 22, 2019 in Xiamen, China. Fruquintinib (Elunate®): Two subgroup analyses will […]
MA14.05 – A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA) Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 – The Adequate MTarget Is Still the Issue Date: Monday, September 09, 2019 Time: 15:45-17:15 Presenter: Shun Lu Authors: Gongyan Chen, Yuping Sun, Sanyuan […]
Contents Corporate Information Contents 1 Financial Highlights 2 Operating Highlights 3 Chairman’s Statement 6 Financial Review 7 Operations Review Innovation Platform Commercial Platform 9 9 19 Condensed Consolidated Balance Sheets 24 Condensed Consolidated Statements of Operations 25 Condensed Consolidated Statements of Comprehensive Loss 26 Condensed Consolidated Statements of Changes in Shareholders’ Equity 27 Condensed Consolidated […]
Announcement released: 7am BST (2pm HKT/2am EDT) >> View Announcement << Presentation webcast & call: 9am BST (4pm HKT/4am EDT) Watch the Webcast Replay US conference call: 9am EDT (2pm BST/9pm HKT) — To participate by phone, please use one of the following numbers. The conference ID for the calls is “Chi-Med“. China Toll […]
London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs. Major highlights include: Positive surufatinib China Phase III study in non-pancreatic neuroendocrine tumors (“NET”) – Interim analysis of SANET-ep study confirmed to […]
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)). An analyst presentation will be […]
Location: 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN, UK Time: 11am
London: Tuesday, February 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (“PRCC”), an investigator initiated study led by Professor Thomas Powles, Lead for […]
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO‑2 Phase III clinical trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, April 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) […]
We are committed to embedding sustainability into all aspects of our operations, creating long-term value for our investors and stakeholders. Building on the substantial initiatives of the previous years and with reference to the latest sustainability standards, we developed a holistic sustainability framework covering areas that are central to our industry – climate action, innovation, […]
View 2023 Report 1. ABOUT THIS REPORT 3 2. 2023 SUSTAINABILITY HIGHLIGHTS 4 3. MESSAGE FROM OUR CHAIRMAN 7 4. ABOUT HUTCHMED 9 5. SUSTAINABILITY GOVERNANCE 15 Sustainability Governance Structure 16 Risk Management 19 Sustainability & Governance Policies 21 6. SUSTAINABILITY STRATEGY 22 Stakeholder Engagement Approach 22 Developing a Holistic Sustainability Strategy 27 7. BUSINESS […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, April 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in […]
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent […]
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and expand indication to more patients — Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 28, 2024: HUTCHMED (China) […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. This follows positive data from the proof-of-concept […]
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, March 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on March 14, 2024, it granted share options (“Share Options”) under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share Option Scheme”) and awards (“LTIP Awards”) under the Long Term Incentive Plan […]
Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status and Breakthrough Therapy designation Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 28, 2024: HUTCHMED […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (“ASCO”) Plenary […]
Hong Kong, Shanghai & Florham Park, NJ — Friday February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the “Options”) pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the […]
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in […]
Job Title: Sales Director / Associate Sales Director Location: Hong Kong Responsibilities Execute company strategies and achieve sales targets within budgets and timescales; Build and maintain a good and sustainable partnership with medical and pharmaceutical professionals; Fulfill the guidelines of internal company policies (e.g. Anti Bribery and Anti Corruption Policy, Code of Ethics etc.); Prepare […]
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — Hong Kong, Shanghai & Florham Park, NJ — Thursday, […]
Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: (a) Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option […]
In anticipation of the expiration of the initial terms of the Framework Sinopharm Products Supply and Purchase Agreement and the HBYS Brand License Royalty Agreement on December 31, 2023, on December 21, 2023: the Company and Sinopharm agreed to renew the Framework Sinopharm Products Supply and Purchase Agreement with effect from January 1, 2024 for […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The study is a […]
Job Title: (Senior/Principal) Clinical Research Physician Location: Shanghai Primary Function Provide medical monitoring for clinical studies. Provide medical leadership on project teams. Participates in development of the Clinical Development (CD) strategy and plan and supports the assigned Medical Director/AD with various deliverables necessary for effective and efficient CD plan execution for the assigned molecule(s)/indication(s). Support […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 1, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Asia Congress, taking place on […]
— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales — Hong Kong, Shanghai & Florham Park, NJ — Wednesday, […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on […]
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration non-small cell lung cancer (“NSCLC”), were presented during the IASLC […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China. The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (“GEJ”) […]
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, where it was designated a Breakthrough Therapy — — Results to be submitted to an upcoming medical meeting — Hong Kong, Shanghai & Florham Park, […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 7, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has issued a total of 3,000,000 ordinary shares of US$0.10 each (“Ordinary Shares”) following the exercise of share options by Dr Weiguo Su, Executive Director, Chief Executive Officer and Chief […]
Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which include US$259 million of the upfront recognized from Takeda) Company to Host Interim Results Call & Webcast Today at […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 20, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with […]
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 13, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that with effect from July 13, 2023: (i) Mr […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, July 10, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective allosteric inhibitor targeting Src homology-2 domain-containing protein tyrosine phosphatase-2 (“SHP2”). The first patient received their first dose on July […]
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, June 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: (a) Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 26, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm […]
Job Title: Clinical Project Manager Location: Shanghai / Beijing / Guangzhou / Nanjing / Hangzhou / Suzhou / Tianjin Primary Function Management of clinical research project. Vendor (CRO, Lab, drug storage, etc.) supervision and management. Liaison with KOLs. Support IND and NDA filing. Quality control of the clinical research projects, such as co-monitoring. Responsibilities Adhere […]
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — Hong Kong, Shanghai, Florham Park, NJ, Osaka, Japan & Cambridge, MA — Friday, June 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) […]
— Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (“BSC”) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer Osaka, Cambridge, MA, Hong Kong, Shanghai & Florham Park, NJ — Thursday, June 15, 2023: – Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, June 9, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to two novel investigational hematological malignancy therapies, HMPL-306 and amdizalisib, will be presented at the upcoming European Hematology Association (“EHA”) Annual Meeting, taking place June 8-11, 2023 in […]
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 5, 2023, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan adopted by HUTCHMED in 2015 (“LTIP”) and share options under the Share Option Scheme adopted by HUTCHMED in […]
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials — OSAKA, Japan, CAMBRIDGE, Massachusetts, HONG KONG, SHANGHAI &, FLORHAM PARK, New Jersey, Friday May 26, 2023 – Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, May 25, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer therapies fruquintinib, surufatinib and HMPL-453 in 21 abstracts that will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, […]
TR-1: Standard form for notification of major holding NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i “>1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: HUTCHMED (China) Limited 1b. Please […]
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 12, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, May 10, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that that Professor Solange Peters is appointed as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma in China has been accepted for review by the China National Medical […]
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, April 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented during the American Association for Cancer Research Annual Meeting 2023 (AACR 2023), which will take […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Karen Jean Ferrante has informed the Company that she would retire from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2023 […]
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study Xiaofan Liu, Hu Zhou, Yu Hu, Jie Yin, Junmin Li, Wenming Chen, Ruibin Huang, Yuping Gong, Chengwei Luo, Heng Mei, Bingjie Ding, Chengyuan Gu, Huiping Sun, Yun Leng, Dexiang Ji, Yan Li, Hongyan Yin, […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 4, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration (“NMPA”) and reached an agreement to initiate the registration phase of the ongoing Phase II trial of HMPL-453 for intrahepatic cholangiocarcinoma (“IHCC”) patients with fibroblast […]
— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in refractory metastatic colorectal cancer (0.66 HR), consistent with the 35% reduction in […]
The outcome for patients in Japan from the FRESCO-2 multi-regional clinical trial of fruquintinib, an oral inhibitor of VEGFR-1, -2 and -3, are being presented at the 2023 Japanese Society of Medical Oncology Annual Meeting, taking place March 16-18 in Fukuoka, Japan. Title: Efficacy and Safety of fruquintinib in Japanese patients with refractory metastatic […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further […]
Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE®, SULANDA® and ORPATHYS® alongside clinical and strategic progress Company to Host Annual Results Call […]
Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib in patients with relapsed or refractory follicular lymphoma (“FL”), a subtype of non-Hodgkin’s lymphoma (“NHL”). The last patient was enrolled on February […]
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and […]
Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung […]
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 3, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) in China. The last patient was enrolled on […]
Hong Kong, Shanghai, & Florham Park, NJ — Friday, December 30, 2022: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant: HUTCHMED (China) Limited 2. Name of scheme: (a) Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option […]
— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% […]
Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today provides a corporate and strategic update, following an in-depth evaluation of the business. In response to the challenging market conditions currently affecting […]
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — — Safety findings consistent with fruquintinib known profile — Hong Kong, Shanghai & Florham Park, NJ — Monday, November 14, 2022: […]
Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The first patient in China received the […]
Hong Kong, Shanghai & Florham Park, NJ –– Monday, October 10, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. wAIHA is an autoimmune disorder that can lead to anemia and has limited […]
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, September 14, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on September 13, 2022, it granted share options under the Share Option Scheme adopted by HUTCHMED in 2015 (the “Share Option Scheme”) and conditional awards (“LTIP Awards”) under the Long Term Incentive Plan adopted […]
Title: FRESCO-2: A global Phase 3 multi-regional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer Presenter: Arvind Dasari, MD, MS, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Session: Proffered Paper session […]
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-breaking, proffered paper presentation at ESMO — — Conference call and webcast to be held on Monday, […]
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: HUTCHMED (China) Limited 1b. Please indicate if the issuer is a non-UK issuer (please […]
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation at the Congress — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August […]
San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals (“Inmagene“) and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (“BTK”) inhibitor. Inmagene is developing the […]
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to be submitted to an upcoming medical meeting — Hong Kong, Shanghai & Florham Park, NJ — Monday, August 8, 2022: […]
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — Hong Kong, Shanghai & Florham Park, NJ — Monday, August 8, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) and AstraZeneca PLC (“AstraZeneca”) […]
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with high MET2 levels and no prior chemotherapy Initiated six new trials thus far in 2022 with a further six starting, […]